Population Pharmacokinetics and Exposure-Response Analyses of an MDM2 Inhibitor Milademetan

被引：0
|
作者：
Kang, Dongwoo [1 ]
Kumar, Prasanna [1 ]
Zernovak, Oleg [1 ]
Song, Saeheum [1 ]
Xiong, Yuan [2 ]
Bergsma, Tim [2 ]
Lovern, Mark [2 ]
Yin, Ophelia [1 ]
机构：
[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[2] Certara, Princeton, NJ USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-045
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [1] MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan
    Tirunagaru, Vijaya G.
    Gounder, Mrinal M.
    Kumar, Prasanna R.
    Hong, David S.
    Doebele, Robert C.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [2] Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan
    Bidard, Francois-Clement
    Roufai, Diana Bello
    Medford, Arielle J.
    Tirunagaru, Vijaya
    Doebele, Robert C.
    Bardia, Aditya
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [3] Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
    Takahashi, Shunji
    Fujiwara, Yutaka
    Nakano, Kenji
    Shimizu, Toshio
    Tomomatsu, Junichi
    Koyama, Takafumi
    Ogura, Mariko
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Yamashita, Tomonari
    Sakajiri, Sakura
    Yamamoto, Noboru
    [J]. CANCER SCIENCE, 2021, 112 (06) : 2361 - 2370
  • [4] Population pharmacokinetics and exposure-response analyses of varenicline in adolescent smokers
    Fediuk, Daryl J.
    Sweeney, Kevin
    Sahasrabudhe, Vaishali
    McRae, Thomas
    Byon, Wonkyung
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (07): : 769 - 781
  • [5] Population Pharmacokinetics and Exposure-Response Analyses for Abatacept in Juvenile Idiopathic Arthritis
    Li, X.
    Passarell, J. A.
    Lin, K.
    Roy, A.
    Murthy, B.
    Girgis, I. G.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S127 - S128
  • [6] Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
    Thakre, Neha
    D'Cunha, Ronilda
    Goebel, Aline
    Liu, Wei
    Pang, Yinuo
    Suleiman, Ahmed A.
    [J]. RHEUMATOLOGY AND THERAPY, 2022, 9 (06) : 1587 - 1603
  • [7] Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis
    Chen, Yang
    Miao, Xin
    Hsu, Chyi-Hung
    Zhuang, Yanli
    Kollmeier, Alexa
    Xu, Zhenhua
    Zhou, Honghui
    Sharma, Amarnath
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 749 - 760
  • [8] Population Pharmacokinetics, Efficacy Exposure-Response Analysis
    Chan, Phyllis
    Yu, Jiajie
    Chinn, Leslie
    Prohn, Marita
    Huisman, Jan
    Matzuka, Brett
    Hanley, William
    Tuckwell, Katie
    Quartino, Angelica
    [J]. PHARMACEUTICAL RESEARCH, 2020, 37 (02)
  • [9] Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
    Kubota, Ryuji
    Fukumura, Kazuya
    Wajima, Toshihiro
    [J]. PHARMACEUTICAL RESEARCH, 2018, 35 (11)
  • [10] Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
    Ryuji Kubota
    Kazuya Fukumura
    Toshihiro Wajima
    [J]. Pharmaceutical Research, 2018, 35
12345